BMS Acquires Cormorant to Expand Immuno-oncology Pipeline
By Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 7 (Table of Contents)
Published: 26 Jul-2016
DOI: 10.3833/pdr.v2016.i7.2176 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Following a string of deals centred around immuno-oncology, Bristol-Myers Squibb has entered into an agreement to acquire Swedish biotech, Cormorant Pharmaceuticals, for up to US$520 M including upfront and contingent payments...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS